136P Tislelizumab (TIS) plus chemotherapy (chemo) for EGFR-mutated non-squamous non-small cell lung cancer (nsq-NSCLC) failed to EGFR tyrosine kinase inhibitors (TKIs) therapies: The primary analysis

B Han,H Zhong,P Tian,Y Zhao,Q Guo,X Yu,Z Yu,X Zhang,Y Li,L Chen,Y Zhang,X Shi,J Wang

doi:10.1016/j.iotech.2022.100248

136P Tislelizumab (TIS) plus chemotherapy (chemo) for EGFR-mutated non-squamous non-small cell lung cancer (nsq-NSCLC) failed to EGFR tyrosine kinase inhibitors (TKIs) therapies: The primary analysis

B Han, H Zhong + Show 11 more

Open Access

https://doi.org/10.1016/j.iotech.2022.100248

Copy DOI

Journal: Immuno-Oncology and Technology	Publication Date: Dec 1, 2022
License type: cc-by-nc-nd

Affiliation: Shanghai Jiao Tong University, Affiliated Hospital of Qingdao University, Henan Cancer Hospital, Shandong First Medical University, West China Hospital of Sichuan University

#Non-squamous Non-small Cell Lung Cancer #Tislelizumab + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Treatment option is limited for EGFR-mutated NSCLC after failure to EGFR TKIs. This multicenter, open-label, phase II study aims to evaluate the efficacy and safety of TIS plus chemo (cohort 1) or TIS plus chemo and bevacizumab (cohort 2) in EGFR-mutated nsq-NSCLC pts failed to EGFR TKI therapies. Herein, the primary analysis of cohort 1 is reported.

Full Text